Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Yoshinobu Okabe

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102241053. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers

Papers 21

  1. Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.gastha.2024.04.011↗
  2. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  3. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  4. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  5. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  6. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. First author DOI 10.1038/s41598-023-46924-0↗
  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  8. KRAS Mutation Analysis Using Cell-free DNA of Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16434↗
  9. Fully covered metal stents vs plastic stents for preoperative biliary drainage in patients with resectable pancreatic cancer without neoadjuvant chemotherapy: … Co-author DOI 10.1002/jhbp.1090↗
  10. Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15913↗
  11. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  12. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  13. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000026052↗
  14. Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00795-019-00218-5↗
  15. A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. Co-author DOI 10.4103/eus.eus_58_17↗
  16. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of th… Co-author DOI 10.1186/s12943-016-0516-4↗
  17. Evaluation of endoscopic cytological diagnosis of unresectable pancreatic cancer prior to and after the introduction of endoscopic ultrasound-guided fine-needl… First author DOI 10.3892/mco.2014.277↗
  18. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  19. Metastatic pulmonary adenocarcinoma 13 years after curative resection for pancreatic cancer: report of a case and review of Japanese literature. Co-author DOI 10.6092/1590-8577/739↗
  20. Accuracy of differential diagnosis for pancreatic cancer is improved in the combination of RCAS1 and CEA measurements and cytology in pancreatic juice. First author DOI 10.1007/s00795-010-0511-6↗
  21. [A pilot study of intraperitoneal gemcitabine for reduction of peritoneal dissemination in advanced pancreatic cancer]. Last author PMID 22202292↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 7 shared papers, 2021–2024 · strength 0.91
  2. Kenji Mitsugi · 7 shared papers, 2021–2024 · strength 0.91
  3. Shiho Arima · 7 shared papers, 2021–2024 · strength 0.91
  4. Futa Koga · 7 shared papers, 2021–2024 · strength 0.91
  5. Taro Shibuki · 7 shared papers, 2021–2024 · strength 0.91
  6. Mototsugu Shimokawa · 7 shared papers, 2021–2024 · strength 0.91
  7. Taiga Otsuka · 7 shared papers, 2021–2024 · strength 0.91
  8. Tsuyoshi Shirakawa · 7 shared papers, 2021–2024 · strength 0.91
  9. Azusa Komori · 7 shared papers, 2021–2024 · strength 0.91
  10. Hiroki Taguchi · 7 shared papers, 2021–2024 · strength 0.91
  11. Yoshiki Naito · 9 shared papers, 2011–2024 · strength 0.91
  12. Keisuke Miwa · 6 shared papers, 2021–2024 · strength 0.79
  13. Masaru Fukahori · 6 shared papers, 2019–2024 · strength 0.71
  14. Yasunori Kawaguchi · 5 shared papers, 2021–2024 · strength 0.64
  15. Jun Akiba · 6 shared papers, 2011–2023 · strength 0.58
  16. Kazuo Nishikawa · 4 shared papers, 2023–2024 · strength 0.54
  17. Shuji Arita · 4 shared papers, 2023–2024 · strength 0.54
  18. Norio Ureshino · 4 shared papers, 2021–2024 · strength 0.52
  19. Yasushi Ide · 4 shared papers, 2021–2024 · strength 0.52
  20. Tomoyuki Ushijima · 5 shared papers, 2014–2023 · strength 0.45
  21. Takuji Torimura · 4 shared papers, 2018–2024 · strength 0.45
  22. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  23. Akio Ido · 3 shared papers, 2023–2024 · strength 0.40
  24. Takahiko Sakaue · 3 shared papers, 2019–2024 · strength 0.37
  25. Toru Hisaka · 3 shared papers, 2012–2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.